Quality of life and its association with direct medical costs for COPD in urban China

Wu, Minmin; Zhao, Qi; Chen, Yue; Fu, Chaowei; Xu, Biao

doi:10.1186/s12955-015-0241-5

Cited by 35 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study has presented evidence of the financial and quality‐of‐life costs to people who have chronic wounds. A further consideration is the relationship between financial cost and quality of life given that research conducted with people who have other chronic conditions, such as COPD and Alzheimer's disease , has shown that poorer quality of life can be associated with higher medical health care costs. It is suggested that increased use of services, associated with better quality of life and help seeking behaviours, is accountable for these findings.…”

Section: Discussionmentioning

confidence: 99%

The financial and quality‐of‐life cost to patients living with a chronic wound in the community

Kapp

Santamaria

2017

International Wound Journal

View full text Add to dashboard Cite

Chronic wounds are associated with financial and personal costs. The system level expense associated with chronic wounds has been established, however, the out-of-pocket cost incurred by individuals who self-fund has not been the focus of extensive investigation. Recently, there has been renewed interest in evaluating quality of life, in line with the shift to patient enablement and self-care in chronic disease management. The objectives of this research were to describe the out-of-pocket wound treatment costs and the quality of life of people who have chronic wounds. A questionnaire incorporating the Cardiff Wound Impact Schedule and purpose-designed instruments was completed by a non-probability, convenience sample of 113 people in Australia and Wales. Data was analysed using descriptive statistics. The sample was on average 63·6 years of age and had wounds that were on an average 109 weeks duration. Participants had spent on average AU$2475 on wound dressing products since the wound started, and AU$121·82 in the most recent 28 days which represented 10% of their disposable income. Health-related quality of life was sub-optimal, 6/10 (ave) according to the Cardiff Wound Impact Schedule. Younger participants reported significantly poorer quality of life on all CWIS sub-scales when compared to older participants. This study found that chronic wounds present a significant financial cost to individuals who must self-fund their wound dressings and other wound treatment related expenses. Participants who had access to wound product subsidisation also experienced personal financial costs. People who have chronic wounds experience sub-optimal quality of life therefore this condition is also costly to the individual's well-being. The quality of life of younger people has not received adequate attention and requires further consideration given the many years that younger people may have to live with this debilitating and often recurrent condition. Continued action is required to reduce the financial and personal costs experienced by people who have chronic wounds. It is imperative that healthcare funding is directed to people who have chronic wounds, in particular to alleviate the out-of-pocket costs experienced by self-funders. Continued attention to the quality of life of people who have chronic wounds is required to minimise the negative effects of this condition and enhance well-being.

show abstract

Section: Discussionmentioning

confidence: 99%

The financial and quality‐of‐life cost to patients living with a chronic wound in the community

Kapp

Santamaria

2017

International Wound Journal

View full text Add to dashboard Cite

show abstract

“…A total of 721 COPD patients were invited and 94% of them were eligible based on the inclusion criteria (local residents who lived in the city for at least 2 years without any unstable comorbidities or any severe conditions needed to be treated as inpatients). COPD cases who did not meet the inclusion criteria were excluded 12. A written informed consent was obtained from all subjects.…”

Section: Methodsmentioning

confidence: 99%

Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities

Chen

Wang

Chen

et al. 2016

COPD

Self Cite

View full text Add to dashboard Cite

PurposeThe economic burden of COPD has not been well studied in China. This study investigated the total costs caused by COPD and the influencing factors for the high economic burden in urban areas of China.Patients and methodsA cross-sectional study was carried out among 678 COPD patients in four cities in China in 2011. The average annual direct medical costs (DMCs), direct nonmedical costs (DNMCs), and indirect costs (ICs) on COPD were measured by median and mean (± standard deviation). Logistic regression model was used to explore factors related to high total costs on COPD.ResultsThe median annual DMCs, DNMCs, and ICs per COPD patient were RMB 5565 Yuan (US$ 862), 0 Yuan (US$ 0), and 0 Yuan (US$ 0), respectively, and the mean annual DMCs, DNMCs, and ICs per COPD patient were RMB 11968 (±22422) Yuan [US$ 1853 (±3472)], 539 (±2092) Yuan [US$ 83 (±324)], and 2087 (±8110) Yuan [US$ 323 (±1256)], respectively. The annual DMCs, DNMCs, and ICs for diagnosed COPD patients were RMB 195.70 billion Yuan (US$ 30.30 billion), 8.78 billion Yuan (US$ 1.36 billion), and 34.10 billion Yuan (US$ 5.28 billion), respectively, in China. Hospitalization accounted for 56.7% of the total costs. High economic burden was significantly related to age, acute exacerbations, and disease severity in COPD patients.ConclusionCOPD posed a heavy economic burden in China. Measures to delay the disease progression and to reduce the risks of acute exacerbation and hospitalization will help substantially lower the costs for COPD care.

show abstract

“…There is no cure for COPD, therefore, the purpose of pharmacological and nonpharmacologic treatments is to mitigate symptoms and improve quality of life [1,2]. Therefore, the healthrelated quality of life (HRQoL) of patients with COPD has been considered an important disease outcome in recent clinical studies [3,4]. Tools assessing HRQoL should be able to differentiate it according to the patient's clinical status [5].…”

Section: Introductionmentioning

confidence: 99%

Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease

et al. 2020

View full text Add to dashboard Cite

Background: The discriminatory ability of multi-attribute utility (MAU) measures compared to condition-specific measures (CSM) in assessing health-related quality of life (HRQoL) among patients with chronic obstructive pulmonary disease (COPD) is an unsettled issue. This study investigated the quality of life of patients with COPD with three different HRQoL instruments and examined whether they could differentiate between adjacent severity groups in a statistically and clinically meaningful manner. In the process, the minimal clinically important differences (MCID) of the EQ-5D utility index were estimated. Methods: Cross-sectional survey data were collected from patients with mild to very severe COPD in South Korea. In addition to demographic and clinical information, the following HRQoL questionnaires were used: The three-level five-dimensional Euro-Quality of Life tool (EQ-5D-3L), the EQ-Visual Analog Scale (EQ-VAS), and the Chronic Obstructive Pulmonary Disease Assessment Test (CAT). Patients' health-related quality of life was analyzed with reference to severity groups based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. To investigate the discriminatory ability of the HRQoL instruments between COPD severity groups, tests examining variance, covariance, and standardized mean difference were performed. After estimating the MCID of the EQ-5D utility index using the anchor-based method, we investigated whether the differences in the EQ-5D utility scores between groups exceeded the clinically meaningful minimum level. Results: A total of 298 patients completed this study. All the quality of life scores showed statistically significant differences between the GOLD severity groups. The pooled MCID estimate for the EQ-5D utility index was 0.028 (range: 0.017-0.033). Even after adjusting for other factors affecting quality of life, the EQ-5D utility index differentiated the GOLD groups well. Conclusions: We conclude that the EQ-5D utility index is a valid instrument for measuring the quality of life of patients with COPD, and the pooled MCID estimate for the EQ-5D utility index was 0.028.

show abstract

Quality of life and its association with direct medical costs for COPD in urban China

Cited by 35 publications

References 29 publications

The financial and quality‐of‐life cost to patients living with a chronic wound in the community

The financial and quality‐of‐life cost to patients living with a chronic wound in the community

Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities

Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About